A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients With Acute Intermittent Porphyria Who Have Completed a Previous Clinical Study With ALN-AS1
Latest Information Update: 15 Mar 2024
At a glance
- Drugs Givosiran (Primary)
- Indications Acute intermittent porphyria
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 24 Jun 2023 Final results assessing the safety and efficacy of up to48 months of givosiran treatment in patients with acute intermittent porphyria, presented at the European Association for the Study of the Liver Congress 2023.
- 24 Jun 2023 Results assessing long-term treatment outcomes, qualitative interviews were conducted with study participants from Phase 1/2(NCT02949830) and Phase 3 (ENVISION; NCT03338816) studies, presented at the European Association for the Study of the Liver Congress 2023.
- 09 Nov 2021 Status changed from active, no longer recruiting to completed.